A large nationwide Korean cohort study using the National Health Insurance Service sample cohort found that adults meeting clinical criteria for insomnia had a higher rate of new temporomandibular disorder (TMD) diagnoses over follow-up: incidence was 6.46 versus 4.48 per 1,000 person‑years and the adjusted hazard ratio was 1.36 (95% CI 1.25–1.49), indicating approximately a one‑third increased risk of TMD among people with clinically defined insomnia after controlling for socioeconomic, lifestyle and medical comorbidities. ([bmcoralhealth.biomedcentral.com](https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-025-06967-3))
Study design and data source
The analysis used the Korean National Health Insurance Service (NHIS) national sample cohort, a longitudinal claims and screening dataset drawn to represent about 2% of the population and followed annually from 2002; the NHIS runs a near‑universal mandatory insurance system that covers the vast majority of Koreans. Investigators identified adults who attended national health screenings between 2011 and 2014, applied exclusion criteria to remove prior cancer, dental trauma and prior insomnia or TMD, and then defined insomnia by diagnostic codes combined with at least seven consecutive days of a hypnotic prescription to increase specificity. Propensity score matching (1:3) produced matched cohorts for time‑to‑event analysis. These design, source and cohort details are described in the study methods and are consistent with established uses of the NHIS and its National Sample Cohort for population epidemiology. ([bmcoralhealth.biomedcentral.com](https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-025-06967-3))
How the finding fits with prior evidence and possible mechanisms
This result echoes earlier population research showing an association between primary sleep disorders and later TMD; a prior nationwide cohort in Korea reported a roughly 44% higher adjusted risk of TMD among people with primary sleep disorders. Experimental and clinical literature supports biologically plausible pathways linking poor sleep to heightened pain sensitivity — sleep loss and disrupted sleep architecture can impair endogenous pain‑inhibitory systems, increase inflammatory signaling and promote central sensitization, all mechanisms that raise vulnerability to musculoskeletal pain conditions including TMD. Together, the longitudinal epidemiology and mechanistic work support the interpretation that chronic sleep disturbance is an independent risk marker for later orofacial pain, even while causality cannot be proven from observational data alone. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8555531/?utm_source=openai))
Clinical and public‑health implications
For clinicians, the study reinforces the value of routinely asking about sleep when evaluating patients with jaw pain, facial pain or other TMD symptoms, and conversely screening patients with chronic insomnia for new or worsening orofacial pain. Multidisciplinary management is the accepted standard for difficult TMD cases: conservative dental/physical therapy, pain management and attention to psychosocial and sleep factors improve outcomes in many patients. Because cognitive behavioral therapy for insomnia (CBT‑I) is the recommended first‑line treatment for chronic insomnia by major clinical bodies and is effective without the adverse effects associated with many long‑term hypnotics, clinicians should prioritize behavioral sleep interventions or referral to CBT‑I where available as part of an integrated approach to patients with coexisting sleep disturbance and orofacial pain. ([vdoc.pub](https://vdoc.pub/documents/orofacial-pain-guidelines-for-assessment-diagnosis-and-management-9t4nkfvgr4u0?utm_source=openai))
Why the finding matters
Insomnia symptoms are common and rising in many populations; U.S. surveillance data show substantial proportions of adults report trouble falling asleep, and chronic insomnia affects a measurable share of adults — meaning the study’s signal could affect sizable numbers of patients and health services if the association is confirmed and addressed in practice. Screening and treating insomnia in primary care, dental and pain clinics could therefore be a pragmatic step to reduce the burden of TMD and improve quality of life for people with coexisting sleep and pain problems. ([cdc.gov](https://www.cdc.gov/nchs/products/databriefs/db436.htm?utm_source=openai))
Limitations and next steps
Important caveats apply. The cohort study used administrative and prescription records to define insomnia and TMD, so diagnostic misclassification is possible despite the investigators’ efforts to increase specificity. Observational designs cannot prove cause and effect; residual confounding and reverse causation (for example, subclinical pain disrupting sleep before a formal TMD diagnosis) cannot be fully excluded. Prospective clinical studies that combine standardized sleep assessments, objective sleep measures (for example, polysomnography) and pain phenotyping, and randomized trials testing whether targeted insomnia treatment reduces new‑onset or persistent TMD, would be the highest‑value next steps. The authors of the study make similar recommendations. ([bmcoralhealth.biomedcentral.com](https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-025-06967-3))
Takeaway for patients and healthcare providers
People with persistent insomnia or worsening jaw or facial pain should tell their clinician; clinicians should ask about sleep when evaluating orofacial pain and consider nonpharmacologic insomnia treatment (CBT‑I) as a first step. Health systems and dental‑pain services may benefit from closer coordination with primary care and sleep medicine to identify and treat coexisting sleep disorders that appear to raise the risk of temporomandibular pain conditions. For background on insomnia prevalence and surveillance in the United States, see CDC data on sleep and sleep problems. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5263087/?utm_source=openai))
Read more on Globally Pulse Health.
